BACKGROUND: We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a "penetrin" peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled. METHODS: Enrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections. RESULTS: Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced. CONCLUSION: This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN.
BACKGROUND: We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a "penetrin" peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled. METHODS: Enrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections. RESULTS: Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced. CONCLUSION: This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN.
Authors: Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee Journal: N Engl J Med Date: 2008-06-19 Impact factor: 91.245
Authors: Ying Xie; Akgül Akpinarli; Charles Maris; Edward L Hipkiss; Malcolm Lane; Eun-Kyung M Kwon; Pawel Muranski; Nicholas P Restifo; Paul Andrew Antony Journal: J Exp Med Date: 2010-02-15 Impact factor: 14.307
Authors: Sergio A Quezada; Tyler R Simpson; Karl S Peggs; Taha Merghoub; Jelena Vider; Xiaozhou Fan; Ronald Blasberg; Hideo Yagita; Pawel Muranski; Paul A Antony; Nicholas P Restifo; James P Allison Journal: J Exp Med Date: 2010-02-15 Impact factor: 14.307
Authors: Craig L Slingluff; Galina V Yamshchikov; Kevin T Hogan; Sarah C Hibbitts; Gina R Petroni; Eric A Bissonette; James W Patterson; Patrice Y Neese; William W Grosh; Kimberly A Chianese-Bullock; Andrea Czarkowski; Patrice K Rehm; Jayashree Parekh Journal: Ann Surg Oncol Date: 2008-10-16 Impact factor: 5.344
Authors: Kathleen Settle; Marshall R Posner; Lisa M Schumaker; Ming Tan; Mohan Suntharalingam; Olga Goloubeva; Scott E Strome; Robert I Haddad; Shital S Patel; Earl V Cambell; Nicholas Sarlis; Jochen Lorch; Kevin J Cullen Journal: Cancer Prev Res (Phila) Date: 2009-07-29
Authors: Carolina L Montes; Andrei I Chapoval; Jonas Nelson; Vbenosa Orhue; Xiaoyu Zhang; Dan H Schulze; Scott E Strome; Brian R Gastman Journal: Cancer Res Date: 2008-02-01 Impact factor: 12.701
Authors: Medea Neek; Jo Anne Tucker; Tae Il Kim; Nicholas M Molino; Edward L Nelson; Szu-Wen Wang Journal: Biomaterials Date: 2017-11-20 Impact factor: 12.479
Authors: Stefan Hartmann; Muna Brisam; Stephan Rauthe; Oliver Driemel; Roman C Brands; Andreas Rosenwald; Alexander C Kübler; Urs D A Müller-Richter Journal: Oncol Lett Date: 2016-08-03 Impact factor: 2.967
Authors: Dan P Zandberg; Sandra Rollins; Olga Goloubeva; Robert E Morales; Ming Tan; Rodney Taylor; Jeffrey S Wolf; Lisa M Schumaker; Kevin J Cullen; Ann Zimrin; Robert Ord; Joshua E Lubek; Mohan Suntharalingam; John C Papadimitriou; Dean Mann; Scott E Strome; Martin J Edelman Journal: Cancer Immunol Immunother Date: 2014-12-24 Impact factor: 6.968
Authors: Aaron P Rapoport; Nicole A Aqui; Edward A Stadtmauer; Dan T Vogl; Yin Yan Xu; Michael Kalos; Ling Cai; Hong-Bin Fang; Brendan M Weiss; Ashraf Badros; Saul Yanovich; Gorgun Akpek; Patricia Tsao; Alan Cross; Dean Mann; Sunita Philip; Naseem Kerr; Andrea Brennan; Zhaohui Zheng; Kathleen Ruehle; Todd Milliron; Scott E Strome; Andres M Salazar; Bruce L Levine; Carl H June Journal: Clin Cancer Res Date: 2014-02-11 Impact factor: 12.531